Related Experiment Videos

Management of type 2 diabetes: new and future developments in treatment

Abd A Tahrani1, Clifford J Bailey, Stefano Del Prato

  • 1Centre of Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK.

Lancet (London, England)
|June 28, 2011
PubMed

Insights

New type 2 diabetes treatments are crucial due to rising cases and complications. Promising strategies include glucagon-like-peptide-1 receptor agonists and novel approaches targeting glucose regulation and insulin action.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) presents increasing prevalence, complex pathogenesis, and progressive complications, necessitating novel therapeutic strategies.
  • Current management requires advancement beyond existing treatments to address the multifaceted nature of T2D.

Purpose of the Study:

  • To review emerging and advanced therapeutic targets for type 2 diabetes.
  • To highlight novel pharmacological approaches for glycemic control and metabolic regulation.

Main Methods:

  • Review of ongoing clinical trials and preclinical assessments of novel drug classes.
  • Analysis of mechanisms of action for new therapeutic agents targeting incretin pathways, glucose transport, and metabolic regulation.

Main Results:

  • Long-acting glucagon-like-peptide-1 receptor agonists demonstrate potential for improving insulin secretion, reducing glucagon, and promoting satiety.
  • Inhibitors of dipeptidyl peptidase 4 are nearing completion, enhancing endogenous incretin effects.
  • Novel agents including sodium-glucose cotransporter 2 inhibitors, 11β-hydroxysteroid dehydrogenase 1 inhibitors, glucokinase activators, and glucagon receptor antagonists are under investigation.
  • Early evidence supports compounds mimicking insulin action and bariatric surgery effects.

Conclusions:

  • A diverse array of innovative therapeutic strategies are in development for type 2 diabetes.
  • These novel approaches target multiple pathways involved in glucose homeostasis and metabolic dysfunction, offering potential for improved patient outcomes.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...